Expert consensus document: A consensus on the medical treatment of acromegaly (Q34406566)

2 August 2017

1 reference

title

Expert consensus document: A consensus on the medical treatment of acromegaly (English)

1 reference

2 August 2017

6

1 reference

2 August 2017

1

Andrea Giustina

1 reference

2 August 2017

7

Aart J van der Lely

1 reference

2 August 2017

12

Shlomo Melmed

1 reference

2 August 2017

5

David R Clemmons

1 reference

2 August 2017

4

Marcello D Bronstein

1 reference

2 August 2017

2

Philippe Chanson

1 reference

2 August 2017

David Kleinberg

3

1 reference

2 August 2017

Christian J Strasburger

8

1 reference

2 August 2017

Steven W Lamberts

9

1 reference

2 August 2017

Ken K Y Ho

10

1 reference

2 August 2017

Felipe F Casanueva

11

1 reference

2 August 2017

Acromegaly Consensus Group

13

1 reference

2 August 2017

25 February 2014

1 reference

Nature Reviews Endocrinology

2 August 2017

1 reference

2 August 2017

10

1 reference

2 August 2017

243-248

1 reference

2 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2014.21

2 August 2017

0 references

cites work

Consensus statement: medical management of acromegaly

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Acromegaly pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Current management practices for acromegaly: an international survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

A consensus on the diagnosis and treatment of acromegaly complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Guidelines for acromegaly management: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly--2011 update: executive summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Medical progress: Acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

A consensus on criteria for cure of acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Meta-analysis on the effects of octreotide on tumor mass in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Clinical, quality of life, and economic value of acromegaly disease control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Octreotide long-acting release (LAR): a review of its use in the management of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Efficacy of long-term lanreotide treatment in patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Place of cabergoline in acromegaly: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Lipodystrophy in patients with acromegaly receiving pegvisomant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Experience from the Argentine Pegvisomant Observational Study: preliminary data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Endocrine aspects of obstructive sleep apnea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Influence of disease control with pegvisomant on sleep apnoea and tongue volume in patients with active acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Automated image analysis of hand radiographs reveals widened joint spaces in patients with long-term control of acromegaly: relation to disease activity and symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Prevalence of vertebral fractures in men with acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Spinal volumetric trabecular bone mass in acromegalic patients: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Cost of clinical management of acromegaly in Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

ACROSTUDY: the first 5 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Long-term experience of pegvisomant therapy as a treatment for acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Combination treatment with somatostatin analogues and pegvisomant in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Disappearance of a GH secreting macroadenoma, during long-term somatostatin analogue administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Mortality in Acromegaly: A Metaanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Factors influencing mortality in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Rapidly reversible myocardial edema in patients with acromegaly: assessment with ultrafast T2 mapping in a single-breath-hold MRI sequence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Increased clinical symptoms of acromegalic arthropathy in patients with long-term disease control: a prospective follow-up study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

AcroBel--the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.21

Change of symptoms and perceived health in acromegalic patients on pegvisomant therapy: a retrospective cohort study within the German Pegvisomant Observational Study (GPOS).

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24566817

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRENDO.2014.21

1 reference

2 August 2017

1 reference